DOCSLIB.ORG

Example Cancer Registry Reportable List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Example Cancer Registry Reportable List Example Cancer Registry Reportable List This list provides example documentation of all conditions a cancer registry may consider reportable depending on the organizations the registry reports its data to. The reportable list for each cancer registry may vary. - It is structured alphabetically by the main histologic term. - Qualifiers and/or adjectives associated with the main term are included only if needed to specify when the condition is reportable. - An asterisk (*) to the right of a term denotes conditions not reportable when arising from skin except at a mucoepidermoid site as defined under Exclusions below. - The abbreviation “NOS” means “Not Otherwise Specified.” Determining Reportable Conditions Using Histologic Terms - Conditions are to be reported if the diagnosis includes the terms cancer, carcinoma, malignant, and lymphoma. - Most leukemias and sarcomas are reportable except as noted as exclusions on the listing. - Other reportable conditions not containing these terms (i.e., refractory anemia, stromal endometriosis, Ewing tumor, carcinofibroma) also are included in this listing. Determining Reportable Conditions Using ICD-O Behavior Codes - All cases with a behavior code of /2 (in situ) or /3 (malignant) in the International Classification of Diseases for Oncology (ICD-O), are reportable neoplasms. - In addition, juvenile or pilocytic astrocytoma with a behavior code of /1 (uncertain/borderline) in ICD-O, Third Edition also is reportable using a behavior code of /3. - Note: If a pathologist verifies an ICD-O behavior code of /0 (benign) or /1 (uncertain) as “in situ” or “malignant,” these cases are reportable. Exclusions Conditions are not to be reported if the diagnosis includes: Cervical intraepithelial neoplasia (CIN). Prostatic intraepithelial neoplasia (PIN). Squamous and basal cell cancers primary to the skin: • Neoplasms, malignant, NOS of the skin (C44.0-C44.9) • Epithelial carcinomas of the skin (C44.0-C44.9) • Squamous cell carcinomas of the skin (C44.0-C44.9) • Basal cell carcinomas of the skin (C44.0-C44.9) Note: The above lesions are reportable for squamous and basal cell cancers originating in mucoepidermoid sites: lip, anus, vulva, vagina, penis or scrotum (ICD-O codes C00.0-C00.9, C21.0, C51.0-C51.9, C52.9, C60.0-60.9, and C63.2). Changes to December 2000 List of Abbreviated Reportable Conditions: • Reportable conditions from both the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) and the Third Edition (ICD-O-3) are included in the listing. • Newly reportable conditions and terms with behavior changed from /1 (borderline) in ICD-O-2 to /3 (malignant) in ICD-O-3 are identified in bold print. These conditions are reportable only when diagnosed on or after January 1, 2001. • Several terms changed behavior from /3 (malignant) in ICD-O-2 to /1 (borderline) in ICD-O-3. These conditions are reportable only when diagnosed prior to January 1, 2001, and are identified in [brackets and italics]. • New terms and synonyms for existing ICD-O codes were added. Abstracting Methods Page 1 of 5 © 2005 AHIMA/NCRA Adamantinoma (long bones, malignant, tibial only) papillary, borderline malignancy Adenoacanthoma papillary mucinous, borderline malignancy Adenocarcinofibroma papillary pseudomucinous, borderline Adenocarcinoma malignancy papillary serous, borderline Adenofibroma (malignant endometrioid only) malignancy pseudomucinous, borderline Adenoma (carcinoid bronchial and malignancy serous, borderline malignancyonly)] cylindroid bronchial only) Cystosarcoma phyllodes (malignant only) Adenosarcoma Cytopenia, refractory with multilineage dysplasia AIN III (anal intraepithelial neoplasia, grade III) Dermatofibrosarcoma Ameloblastoma (malignant only) Diktyoma (exclude benign) Androblastoma (malignant only) DIN III (ductal intraepithelial neoplasia, grade III) Anemia, refractory Disease (include only: Angioendotheliomatosis alpha heavy chain Angiomyosarcoma Bowen* Angiosarcoma Di Guglielmo Argentaffinoma (malignant only) Franklin Arrhenoblastoma (malignant only) gamma heavy chain Astroblastoma Heavy chain NOS Astrocytoma (exclude subependymal and Hodgkin desmoplastic infantile) immunoproliferative [NOS and small intestinal Astroglioma only] Blastoma* Letterer-Siwe Cancer* mast cell, systemic tissue Carcinoid (exclude tumor of appendix, strumal, Mu heavy chain argentaffin tumor NOS, Myeloproliferative, chronic, NOS enterochromaffin-like cell NOS, and tubular) Paget* [exclude of bone] Carcinofibroma Sezary) Carcinoma* Disorder, myeloproliferative, chronic Carcinomatosis* Disorder, primary cutaneous CD30+ T-cell Carcinosarcoma lymphoproliferative CASTLE (Carcinoma showing thymus-like element) Dysgerminoma Chloroma Ectomesenchymoma Cholangiocarcinoma Endometriosis, stromal Chondroblastoma (malignant only) Enteroglucagonoma (malignant only) Chondrosarcoma Ependymoblastoma Chordoma Ependymoma (exclude myxopapillary) Choriocarcinoma Epithelioma* (NOS, basal cell, malignant, and squamous Chorioepithelioma cell only) Chorionepithelioma Erythremia (acute and chronic only) Class IV cytology Erythroleukemia Class V cytology Erythroplasia, Queyrat* Comedocarcinoma Esthesioneuroblastoma CPNET (central primitive neuroectodermal, NOS) Esthesioneurocytoma Cylindroma (exclude eccrine dermal, and skin) Esthesioneuroepithelioma Cyst (dermoid with malignant transformation only or Fibrochondrosarcoma dermoid with secondary tumor) Fibrodentinosarcoma Cystadenocarcinofibroma Fibroepithelioma, of Pinkus type or NOS* Cystadenocarcinoma Fibroliposarcoma Cystadenofibroma (malignant endometrioid only) Fibromyxosarcoma [Cystadenoma (diagnosis date prior to January 1, 2001); Fibro-odontosarcoma (mucinous, borderline malignancy Fibrosarcoma Abstracting Methods Page 2 of 5 © 2005 AHIMA/NCRA Fibroxanthoma (malignant only) Medulloepithelioma Ganglioglioma (anaplastic) Medullomyoblastoma Ganglioneuroblastoma Melanoma (exclude juvenile) Gastrinoma (malignant only) Melanomatosis, meningeal Gemistocytoma Melanosis (precancerous only) Germinoma Meningioma (malignant, anaplastic, papillary, or GIST-Gastrointestinal stromal tumor (malignant only) rhabdoid only) Glioblastoma Mesenchymoma (malignant only) Glioma (exclude nasal and subependymal) Mesonephroma (exclude benign) Gliomatosis cerebri Mesothelioma (exclude benign and cystic) Gliosarcoma Metaplasia, agnogenic myeloid Glomangiosarcoma Microglioma Glucagonoma (malignant only) MPNST, NOS (malignant peripheral nerve sheath Granuloma (Hodgkin only) tumor) Hemangioendothelioma (malignant only) Mycosis fungoides Hemangiopericytoma (malignant only) Myelofibrosis (acute, chronic idiopathic, with myeloid Hemangiosarcoma metaplasia or as a result of myeloproliferative Hepatoblastoma disease only) Hepatocarcinoma Myeloma Hepatocholangiocarcinoma Myelomatosis Hepatoma (exclude benign) Myelosclerosis (megakaryocytic, acute, malignant or with Hidradenocarcinoma myeloid metaplasia) Hidradenoma (malignant only) Myelosis Histiocytoma (malignant fibrous only) Myoblastoma (malignant granular cell only) Histiocytosis (malignant, and acute progressive X only) Myoepithelioma (malignant only) Histiocytosis, Langerhans cell, disseminated or Myosarcoma generalized Myosis, stromal NOS or endolymphatic stromal Hutchinson melanotic freckle (melanoma In situ only) Myxoliposarcoma Hypernephroma Myxosarcoma Immunocytoma Neoplasia, ductal intraepithelial, grade 3 (of breast, Insulinoma (malignant only) also called DIN III) LCIS, NOS (lobular carcinoma in situ) Neoplasia, intratubular germ cell Leiomyosarcoma Neoplasia, lobular, grade 2 of breast only (also called Lentigo maligna LN2) Leukemia (exclude granular lymphocytic) Neoplasia, squamous intraepithelial, grade 3 Linitis plastica (of anus, vulva and vagina only - also called, Liposarcoma (exclude well differentiated liposarcoma, AIN III, VIN III and VAIN III) superficial) Neoplasm, malignant* LN2 (of breast also called lobular neoplasia, grade 2 only) Nephroblastoma Lymphangioendothelioma (malignant only) Nephroma (exclude mesoblastic) Lymphangiosarcoma Neurilemmoma (malignant only) Lymphoblastoma Neurilemmosarcoma Lymphoepithelioma* Neuroblastoma Lymphoma Neurocytoma, olfactory Lymphosarcoma Neuroepithelioma Macroglobulinemia, Waldenstrom Neurofibrosarcoma Malignancy* Neurosarcoma Malignant* Nevus (malignant blue only) Mastocytoma (malignant only) Odontosarcoma Mastocytosis (malignant only) Oligoastrocytoma, mixed Medulloblastoma Oligodendroblastoma Abstracting Methods Page 3 of 5 © 2005 AHIMA/NCRA Oligodendroglioma Struma (malignant ovarii and Wuchernde Orchioblastoma Langhans only) Osteochondrosarcoma Sympathicoblastoma Osteoclastoma (malignant only) Syndrome, Osteofibrosarcoma 5q deletion with myelodysplastic Osteosarcoma syndrome Pancreatoblastoma Hypereosinophilic Panmyelosis, acute only Myelodysplastic NOS Papilloma, choroid plexus (anaplastic and with 5q deletion syndrome malignant only) therapy-related, NOS Papulosis, lymphomatoid therapy-related, alkylating agent Paraganglioma (malignant only) related Paragranuloma, Hodgkin therapy-related, epidopophyllotoxin related Perineural MPNST Preleukemic Perineurioma (malignant only) Sezary Pheochromoblastoma Synovioma (NOS and malignant only) Pheochromocytoma (malignant only) Syringoma chondroid, (malignant only) Pilomatrixoma* (malignant only) Teratoblastoma, malignant Pineoblastoma Teratocarcinoma Plasmacytoma Teratoma (embryonal, immature, malignant, and with PNET (primitive neuroectodermal tumor) malignant transformation only) Pneumoblastoma Thecoma (malignant only) Polycythemia (proliferative,
Load more

Recommended publications
  • Central Nervous System Cancers Panel Members Can Be Found on Page 1151
    1114 NCCN David Tran, MD, PhD; Nam Tran, MD, PhD; Frank D. Vrionis, MD, MPH, PhD; Patrick Y. Wen, MD; Central Nervous Nicole McMillian, MS; and Maria Ho, PhD System Cancers Overview In 2013, an estimated 23,130 people in the United Clinical Practice Guidelines in Oncology States will be diagnosed with primary malignant brain Louis Burt Nabors, MD; Mario Ammirati, MD, MBA; and other central nervous system (CNS) neoplasms.1 Philip J. Bierman, MD; Henry Brem, MD; Nicholas Butowski, MD; These tumors will be responsible for approximately Marc C. Chamberlain, MD; Lisa M. DeAngelis, MD; 14,080 deaths. The incidence of primary brain tumors Robert A. Fenstermaker, MD; Allan Friedman, MD; Mark R. Gilbert, MD; Deneen Hesser, MSHSA, RN, OCN; has been increasing over the past 30 years, especially in Matthias Holdhoff, MD, PhD; Larry Junck, MD; elderly persons.2 Metastatic disease to the CNS occurs Ronald Lawson, MD; Jay S. Loeffler, MD; Moshe H. Maor, MD; much more frequently, with an estimated incidence ap- Paul L. Moots, MD; Tara Morrison, MD; proximately 10 times that of primary brain tumors. An Maciej M. Mrugala, MD, PhD, MPH; Herbert B. Newton, MD; Jana Portnow, MD; Jeffrey J. Raizer, MD; Lawrence Recht, MD; estimated 20% to 40% of patients with systemic cancer Dennis C. Shrieve, MD, PhD; Allen K. Sills Jr, MD; will develop brain metastases.3 Abstract Please Note Primary and metastatic tumors of the central nervous system are The NCCN Clinical Practice Guidelines in Oncology a heterogeneous group of neoplasms with varied outcomes and (NCCN Guidelines®) are a statement of consensus of the management strategies.
    [Show full text]
  • Malignant Glioma Arising at the Site of an Excised Cerebellar Hemangioblastoma After Irradiation in a Von Hippel-Lindau Disease Patient
    DOI 10.3349/ymj.2009.50.4.576 Case Report pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 50(4): 576-581, 2009 Malignant Glioma Arising at the Site of an Excised Cerebellar Hemangioblastoma after Irradiation in a von Hippel-Lindau Disease Patient Na-Hye Myong1 and Bong-Jin Park2 1Department of Pathology, Dankook University College of Medicine, Cheonan; 2Department of Neurosurgery, Kyunghee University Hospital, Seoul, Korea. We describe herein a malignant glioma arising at the site of the resected hemangioblastoma after irradiation in a patient with von Hippel-Lindau disease (VHL). The patient was a 25 year-old male with multiple heman- gioblastomas at the cerebellum and spinal cord, multiple pancreatic cysts and a renal cell carcinoma; he was diagnosed as having VHL disease. The largest hemangioblastoma at the right cerebellar hemisphere was completely removed, and he received high-dose irradiation postoperatively. The tumor recurred at the same site 7 years later, which was a malignant glioma with no evidence of hemangioblastoma. The malignant glioma showed molecular genetic profiles of radiation-induced tumors because of its diffuse p53 immunostaining and the loss of p16 immunoreactivity. The genetic study to find the loss of heterozygosity (LOH) of VHL gene revealed that only the cerebellar hemangioblastoma showed allelic losses for the gene. To the best of our knowledge, this report is the first to show a malignant glioma that developed in a patient with VHL disease after radiation therapy at the site of an excised hemangioblastoma. This report also suggests that radiation therapy should be performed very carefully in VHL patients with hemangioblastomas.
    [Show full text]
  • Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart
    Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor
    [Show full text]
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • PROPOSED REGULATION of the STATE BOARD of HEALTH LCB File No. R057-16
    PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 Section 1. Chapter 457 of NAC is hereby amended by adding thereto the following provision: 1. The Division may impose an administrative penalty of $5,000 against any person or organization who is responsible for reporting information on cancer who violates the provisions of NRS 457. 230 and 457.250. 2. The Division shall give notice in the manner set forth in NAC 439.345 before imposing any administrative penalty 3. Any person or organization upon whom the Division imposes an administrative penalty pursuant to this section may appeal the action pursuant to the procedures set forth in NAC 439.300 to 439. 395, inclusive. Section 2. NAC 457.010 is here by amended to read as follows: As used in NAC 457.010 to 457.150, inclusive, unless the context otherwise requires: 1. “Cancer” has the meaning ascribed to it in NRS 457.020. 2. “Division” means the Division of Public and Behavioral Health of the Department of Health and Human Services. 3. “Health care facility” has the meaning ascribed to it in NRS 457.020. 4. “[Malignant neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. [4] “Medical laboratory” has the meaning ascribed to it in NRS 652.060. 5. “Neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. 6. “[Physician] Provider of health care” means a [physician] provider of health care licensed pursuant to chapter [630 or 633] 629.031 of NRS. 7. “Registry” means the office in which the Chief Medical Officer conducts the program for reporting information on cancer and maintains records containing that information.
    [Show full text]
  • Rare Pancreatic Tumors
    Published online: 2020-04-29 THIEME 64 ReviewRare Pancreatic Article Tumors Choudhari et al. Rare Pancreatic Tumors Amitkumar Choudhari1,2 Pooja Kembhavi1,2 Mukta Ramadwar3,4 Aparna Katdare1,2 Vasundhara Smriti1,2 Akshay D. Baheti1,2 1Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Address for correspondence Akshay D. Baheti, MD, Department of Maharashtra, India Radiodiagnosis, Tata Memorial Hospital, Ernest , Borges Marg Parel 2Department of Radiodiagnosis, Homi Bhabha National University, Mumbai 400012, India (e-mail: [email protected]). Mumbai, Maharashtra, India 3Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India 4Department of Pathology, Homi Bhabha National University, Mumbai, Maharashtra, India J Gastrointestinal Abdominal Radiol ISGAR 2020;3:64–74 Abstract Pancreatic ductal adenocarcinoma, neuroendocrine tumor, and cystic pancreatic neo- plasms are the common pancreatic tumors most radiologists are familiar with. In this Keywords article we review the clinical presentation, pathophysiology, and radiology of rare pan- ► pancreatic cancer creatic neoplasms. While the imaging features are usually nonspecific and diagnosis is ► uncommon based on pathology, the radiology along with patient demographics, history, and lab- ► pancreatoblastoma oratory parameters can often help indicate the diagnosis of an uncommon pancreatic ► acinar cell neoplasm and guide appropriate management in these cases. ► lymphoma Introduction hyperlipasemia may rarely lead to extraabdominal manifes- tations like ectopic subcutaneous fat necrosis and polyarthri- Pancreatic tumors of various histological subtypes can be tis (lipase hypersecretion syndrome).4 encountered in clinical practice, most common being pan- These tumors are hypoenhancing compared with the pan- creatic ductal adenocarcinoma (PDAC), which constitutes creas and are frequently associated with cystic or necrotic 85% of all pancreatic neoplasms.1 Histologically pancreat- areas as well as calcifications5,6 (►Fig.
    [Show full text]
  • Solid Tumour Section Mini Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Solid Tumour Section Mini Review Lung: Pleuropulmonary blastoma Y Albert Yeh, Morris C Edelman North Shore University Hospital, Long Island Jewish Medical Center, Hofstra University School of Medicine, New York, USA (YAY, MCE) Published in Atlas Database: July 2010 Online updated version : http://AtlasGeneticsOncology.org/Tumors/PleuropulmblastomID6040.html DOI: 10.4267/2042/45006 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology arising in mesenchymal cystic hamartoma, pulmonary Identity blastoma associated with cystic lung disease of Note childhood. Pleuropulmonary blastoma is a rare aggressive malignant tumor of infancy and early childhood. The Clinics and pathology tumor arises in the lung and pleura and is regarded as a pulmonary dysontogenetic or embryonic neoplasm. It is Epidemiology the pulmonary analog of other tumors of childhood There are over 120 cases registered with The including Wilms' tumor, neuroblastoma, Pleuropulmonary Blastoma Registry hepatoblastoma, pancreatoblastoma, and (www.ppbregistry.org). The tumor affects mainly in retinoblastoma. children with age ranges from 1 month to 12 years. Synonyms include embryonal rhabomyosarcoma Most cases are diagnosed before 4 years of age. It can arising in congenital bronchogenic cyst, be found prenatally or present in older children and rhabdomyosarcoma arising in congenital cystic young adults. Males and females are equally affected. adenomatoid malformation, pulmonary sarcoma (A) Type I pleuropulmonary blastoma consists of multiloculated cyst filled with scanty clear serous fluid. (B) The cysts are lined by cuboidal epithelium resting on loose mesenchymal tissue.
    [Show full text]
  • A Rare Disease in Pediatric Patients
    Cartas ao Editor Jornal de Pediatria - Vol. 85, Nº 3, 2009 277 Resposta do autor Gliomatose leptomeníngea primária difusa: uma doença rara em pacientes pediátricos Prezado Editor, Recebemos com prazer os comentários acima. Os autores esclarecem que, em momento algum, focaram suas preo- Prezado Editor, cupações em critérios para definir síndrome metabólica, até mesmo porque se ela existe1, não existem critérios de consenso O recente relato de caso de Val Filho & Avelar1 sobre um para o diagnóstico em adultos2,3 tampouco em adolescentes. raro tumor cerebral pediátrico é interessante e merece grande Preocupamo-nos sim, em mostrar a presença de fatores de consideração no contexto da literatura publicada sobre esse risco em uma amostra selecionada ao acaso, que eles existem assunto, já que representa um evento muito incomum. Em em proporções tais que podem até ser agrupados, e, por um nome da precisão científica, devemos, portanto, fazer uma dos muitos critérios sugeridos na literatura, com valores de importante correção no que se refere ao diagnóstico. referências pediátricos, dar origem ao que se denomina sín- Os autores fizeram uma revisão breve e adequada sobre a drome metabólica. Não nos propusemos, portanto, a estudar gliomatose cerebral; uma doença rara, classificada pela edição associações entre fatores de risco. de 2007 da Organização Mundial da Saúde (OMS)2 como uma Os autores acreditam que discutir critérios para o que não lesão de grau III com prognóstico reservado. A gliomatose 2,3 existe consenso é desfocar a atenção da gravidade
    [Show full text]
  • 6 Magnetic Resonance Imaging
    Chapter 6 / MRI 105 6 Magnetic Resonance Imaging Paul M. Ruggieri Summary Magnetic resonance (MR) is clearly the accepted imaging standard for the preliminary evalua- tion, peri-operative management, and routine longitudinal follow-up of patients with high-grade glio- mas (HGG). The purpose of this chapter is to review the imaging characteristics of HGG using conventional MR imaging techniques. Whereas the newer techniques of MR diffusion, perfusion, diffusion tensor imaging, and MR spectroscopy will be included as part of this discussion of the high grade neoplasms, the detailed concepts of such studies will be discussed elsewhere in this text. Key Words: MR imaging; anaplastic astrocytoma; glioblastoma multiforme; gliosarcoma; gliomatosis cerebri; oligodendroglioma. INTRODUCTION Magnetic resonance (MR) is clearly the accepted imaging standard for the preliminary evaluation, peri-operative management, and routine longitudinal follow-up of patients with high-grade gliomas (HGG). The purpose of this chapter is to review the imaging characteristics of HGG using conventional MR imaging techniques. Whereas the newer techniques of MR diffusion, perfusion, diffusion tensor imaging, and MR spectroscopy will be included as part of this discussion of the high grade neoplasms, the detailed concepts of such studies will be discussed elsewhere in this text. In general terms, high-grade glial neoplasms are conventionally thought of as infiltrative parenchymal masses that are hyperintense on FLAIR fluid-attenuated inversion recovery (FLAIR) and T2-weighted images, hypointense on unenhanced T1-weighted images, may or may not extend into the corpus callosum, are surrounded by extensive vasogenic edema, and prominently enhance following gadolinium administration. It must be pointed out that this description is clearly just a generalization as many high-grade neoplasms clearly do not follow these “rules” and some of these characteristics may even be seen in low-grade neoplasms.
    [Show full text]
  • TUMOR and STAGING DATA Primary Site Code
    SECTION IV - TUMOR and STAGING DATA Primary Site Code NAACCR Version 11.1 field "Primary Site", Item 400, columns 291-294 It is unclear how the 2007 MP/H rules may alter rules for assigning the best Primary Site Formatted: Left Code to each primary. Continue to use the following rules until new rules are issued. Enter the code for the site of origin from the Topography section of ICD-O-3. [Note that ICD-O-2 code C14.1, laryngopharynx, should not be used for diagnoses made on or after January 1, 1995. "Laryngopharynx" became an equivalent term under C13.9 (hypopharynx, NOS) as of this diagnosis date. Code C14.1 is not an ICD-O-3 code.] Enter the site code that matches the narrative primary site indicated in the medical record, or the site code most appropriate for the case. Site codes are found in ICD-O-3's Numerical Lists - Topography section (pages 45-65) and in its Alphabetic Index (pages 105-218). In ICD-O-3 primary site codes consist of the letter "C" followed by two digits, a decimal point, and a third digit. "C" should be entered but the decimal point should not be entered. Example: The primary site is "cardia of stomach". Look this up in the Alphabetic Index of ICD-O-3 under "stomach" or "cardia", and the corresponding code "C16.0" is found. Enter C160. Most sites include a third digit of "8" to be used for single tumors that overlap the boundaries of two or more anatomically contiguous subsites and whose exact point of origin cannot be determined, unless the combination of sites is specifically indexed elsewhere.
    [Show full text]
  • Gastric Cancer: Surgery and Regional Therapy Epidemiology Risk Factors
    Gastric Cancer: Epidemiology Surgery and Regional Therapy Gastric cancer is second leading cause of cancer Timothy J. Kennedy, MD specific mortality world wide (989,600 cases; 738,000 Montefiore Medical Center deaths) accounting for 8% new cancer cases Assistant Professor of Surgery Fourth leading cause of cancer death in the United Upper Gastrointestinal and Pancreas Surgery States (21,320 cases; 10,540 deaths) December 15, 2012 Incidence in Japan 8x higher than US More common in men More common in Asians, blacks, native americans and US hispanics Peak age is 7th decade Incidence of proximal gastric cancer increasing 1 Risk factors Etiology H-pylori infection (90% intestinal type and 30% diffuse type) Exposure to carcinogens (tobacco, salt, nitrites) Pernicious anemia Obesity Adenomatous Polyp Previous gastric surgery Familial history of gastric cancer 4 Molecular Pathogenesis Molecular Pathogenesis Diffuse Type (linitis plastica) Histologic Types (Lauren Classification) Poorly differentiated signet ring cells Intestinal Type (well differentiated) Loss of expression of E-cadherin, a key intercellular Arises from gastric mucosa adhesion molecule which maintains organization of Most common in high risk patient populations epithelial tissue Related to environmental factors Arises within lamina propria of stomach wall and grows in infiltrative/submucosal pattern Associated with older patients and distal tumors Associated with females, younger patients and Incidence is decreasing proximal tumors Better prognosis Associated with early metastases
    [Show full text]
  • 2018 SEER Solid Tumor Manual
    4/6/2018 Eight Groups are Revised for 2018 Head & Neck Colon (includes rectosigmoid and rectum for cases diagnosed 1/1/2018 forward) 2018 SEER Lung (2018 Draft not yet available) Breast Solid Tumor Manual Kidney Urinary Sites (2018 Draft not yet available) 2018 KCR SPRING TRAINING Non‐malignant CNS (2018 Draft not yet available) Malignant CNS and Peripheral Nerves (2018 Draft not yet available) 2019 Changes for other two Groups Solid Tumor Rules What we will cover: ◦ Overview of General rules Cutaneous melanoma (minor revisions and draft available now) • Cutaneous melanoma site rules will be revised for 2019 implementation to incorporate ◦ New Head and Neck rules information from the new WHO 4th Ed Tumors of Skin scheduled to be released in 2018. ◦ New Colorectal rules ◦ New Breast rules Other sites (minor revisions and draft available now) ◦ New Kidney rules • Primary sites excluded are: •Rectosigmoid and rectum which are included in 2018 Colon rules. •Peripheral nerves which are included in 2018 Malignant Brain rules. •Other sites rules will be revised for 2019 implementation. The Solid Tumor Task Force has identified Remember: These are currently in draft form and may change slightly in the final version! the need to expand the rules to include GYN, soft tissue, thyroid and other site‐specific solid tumors. NEW! Code subtypes/variants when definitively described (with no modifiers) General Instructions Example: Well ‐differentiated neuroendocrine tumor 8240. Do not code a histology (*including subtypes or variants) when described as below: The 2018 solid tumor rules replace all previous MP/H rules, but they are effective for diagnoses on or after 1/1/2018.
    [Show full text]